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Summary
Background Mortality remains unacceptably high in patients with heart failure and reduced left ventricular ejection 
fraction (LVEF) despite advances in therapeutics. We hypothesised that a novel artificial intelligence approach could 
better assess multiple and higher-dimension interactions of comorbidities, and define clusters of β-blocker efficacy in 
patients with sinus rhythm and atrial fibrillation.
Methods Neural network-based variational autoencoders and hierarchical clustering were applied to pooled individual 
patient data from nine double-blind, randomised, placebo-controlled trials of β blockers. All-cause mortality during 
median 1·3 years of follow-up was assessed by intention to treat, stratified by electrocardiographic heart rhythm. The 
number of clusters and dimensions was determined objectively, with results validated using a leave-one-trial-out 
approach. This study was prospectively registered with ClinicalTrials.gov (NCT00832442) and the PROSPERO 
database of systematic reviews (CRD42014010012).
Findings 15 659 patients with heart failure and LVEF of less than 50% were included, with median age 65 years 
(IQR 56–72) and LVEF 27% (IQR 21–33). 3708 (24%) patients were women. In sinus rhythm (n=12 822), most clusters 
demonstrated a consistent overall mortality benefit from β blockers, with odds ratios (ORs) ranging from 0·54 to 0·74. 
One cluster in sinus rhythm of older patients with less severe symptoms showed no significant efficacy (OR 0·86, 
95% CI 0·67–1·10; p=0·22). In atrial fibrillation (n=2837), four of five clusters were consistent with the overall neutral 
effect of β blockers versus placebo (OR 0·92, 0·77–1·10; p=0·37). One cluster of younger atrial fibrillation patients at 
lower mortality risk but similar LVEF to average had a statistically significant reduction in mortality with β blockers 
(OR 0·57, 0·35–0·93; p=0·023). The robustness and consistency of clustering was confirmed for all models (p<0·0001 
vs random), and cluster membership was externally validated across the nine independent trials.
Interpretation An artificial intelligence-based clustering approach was able to distinguish prognostic response from 
β blockers in patients with heart failure and reduced LVEF. This included patients in sinus rhythm with suboptimal 
efficacy, as well as a cluster of patients with atrial fibrillation where β blockers did reduce mortality.
Funding Medical Research Council, UK, and EU/EFPIA Innovative Medicines Initiative BigData@Heart.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Advances in therapeutics have substantially improved 
the prognosis of patients with heart failure with reduced 
ejection fraction (HFrEF). However, mortality remains 
unacceptably high (ie, greater than most cancers), 
especially in the majority of patients in clinical practice 
with multimorbidity—eg, atrial fibrillation, which is 
common in patients with HFrEF1,2 and is associated with 
a considerably worse prognosis.3 In contrast to patients 
in sinus rhythm, β-adrenergic blockers, which are a 
cornerstone of heart failure treatment, were not shown 
to reduce mortality in patients with concomitant atrial 
fibrillation.4 Within the subgroup of patients with 
atrial fibrillation, conventional statistical analysis was 
unable to identify any single patient characteristic that 
determined efficacy in these patients.4
With prevalence of atrial fibrillation expected to 
double in the coming decades,5 better identification of 
patient subgroups that could benefit from therapy is 
critical to address this unsustainable burden on health-
care services.6 Conversely, the ability to identify 
individuals who are unlikely to receive therapeutic 
benefit could allow for a more personalised medicine 
approach, by stratifying the use of additional 
management strategies available in clinical practice. 
This approach also applies to patients in sinus 
rhythm—although β blockers show 4% absolute risk 
reduction in mortality, the mortality rate in patients 
randomly assigned to β blockers was still 14% during 
18 months of follow-up.4 Pipeline therapies in 
development could be used to target patients who are 
predicted to have a suboptimal response.7
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We hypothesised that artificial intelligence clustering 
techniques could establish distinct categories of patients 
corresponding to therapeutic efficacy, in individuals 
with sinus rhythm and atrial fibrillation. Unsupervised 
machine learning approaches have the potential to 
exceed preconceived associations, taking into account 
interactions beyond the capabilities of conventional 
statistical analysis.8,9 We designed and tested a novel 
clustering approach in double-blind data from land-
mark randomised controlled trials (RCTs), with 




This study was performed by the cardAIc group at 
the University of Birmingham and University Hospital 
Birmingham NHS Foundation Trust, UK, using 
individual patient data (IPD) from double-blind, 
placebo-controlled RCTs collated by the Beta-blockers 
in Heart Failure Collaborative Group (BB-meta-HF).
This international academic consortium was 
established to bring together investigators and 
pharmaceutical companies to address questions about 
the therapeutic efficacy of β blockers, and important 
clinical comorbidities in heart failure.10–13 In brief, RCTs 
were eligible for inclusion if they recruited more 
than 300 patients, were not confounded by investigation 
of other treatments, had a planned follow-up of 
more than 6 months, and explicitly reported mortality as 
an endpoint.10 The planned studies by BB-meta-HF 
were prospectively registered with ClinicalTrials.gov 
(NCT00832442) and the PROSPERO database of 
systematic reviews (CRD42014010012).14 Nine RCTs of 
β blockers versus placebo which assessed patients in 
sinus rhythm and atrial fibrillation were included. 
The full list of included and excluded trials is presented 
in the appendix (p 7). Using the Cochrane Collaborations 
Risk of Bias Tool, we established that each trial had 
low risk of bias.15 All included studies had appropriate 
ethical approval.
A standardised data request form to obtain IPD from 
each trial has been published, along with search results 
and individual study demographics.10 IPD were extracted 
from original source files and all data were cross-checked 
and compared with published reports. Discrepancies, 
inconsistencies, and incomplete data were checked 
against original case report forms and trial documentation 
to ensure IPD integrity. Trial databases were then 
harmonised according to the standardised data approach 
to match patient characteristics and outcomes across 
all trials.
Population and data
Participants with left ventricular ejection fraction (LVEF) 
of 50% or more were excluded due to previous analysis 
demonstrating a lack of efficacy from β blockers 
regardless of rhythm.12 The remainder were stratified by 
heart rhythm on the baseline electrocardiogram (ECG) 
into sinus rhythm or atrial fibrillation. Atrial flutter was 
included in the atrial fibrillation group, but accounted for 
only 4%.4 Individuals with a missing ECG or paced 
rhythm were excluded. To identify meaningful pheno-
typic subgroups, we prespecified a list of common 
variables available at baseline that are known to be 
relevant to outcomes in patients with HFrEF; namely, 
age, gender, body-mass index, heart rate, systolic blood 
pressure, LVEF, previous myocardial infarction, New York 
Research in context
Evidence before this study
A search of PubMed (from database inception to May 25, 2021) 
using title or abstract terms “clustering” or “sub-group”, 
combined with title, abstract, or MeSH terms for “heart failure”, 
without language or other restrictions, identified 391 results 
(excluding duplicates). 19 of the studies identified were 
evaluated at a full-text level, 12 of which were related to 
clustering approaches in patients with heart failure. A wide 
variety of clustering methods was used in these studies, with a 
lack of transparency in methods, insufficient assessment of the 
robustness of cluster membership, and only one study with 
external validation.
Added value of this study
Using individual patient data from double-blind, randomised 
controlled trials, we determined clusters of patients with heart 
failure and reduced ejection fraction with differing prognostic 
response to β blockers. Identifying distinct clusters of patients, 
including in sinus rhythm with a lack of treatment response and 
in atrial fibrillation with significant mortality benefit from 
β blockers, this study provides a novel method to better classify 
patients with heart failure. The artificial intelligence pipeline 
developed is a model for future analysis across other medical 
conditions, with objective assessment and assignment to 
clusters, robust analysis of the consistency of clustering, and 
external cross validation.
Implications of all the available evidence
Artificial intelligence-based clustering approaches are able to 
incorporate and simultaneously adjust for multiple 
comorbidities. Their use could allow for more refined 
stratification of treatment response to common clinical 
treatments, leading to avoidance of adverse outcomes. 
Prospective evaluation in a randomised setting is now 
warranted to evaluate if these approaches are valuable in 
routine practice to improve patient prognosis, particularly in 
conditions such as heart failure, which remains a key driver of 
health-care cost and poor patient quality of life.
See Online for appendix
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Heart Association class (I or II vs III or IV), creatinine, 
and baseline drug therapy (angiotensin-converting 
enzyme inhibitor, angiotensin receptor blocker, diuretics, 
anticoagulants and digoxin). To avoid introducing bias for 
data not missing completely at random, only participants 
with complete case data for all variables were used to 
establish the clustering subsets.
Variational autoencoders (VAEs), a neural network-
based approach, were used for dimensionality reduction. 
VAEs can cater for heterogeneous data types, including 
numerical and nominal variables using different 
likelihood models (appendix pp 2, 13). Compared with 
conventional principal component analysis (PCA), the 
VAE method allows for discovery of complex non-linear 
relationships, and was significantly better in this dataset 
(average best gap statistic value 0·812 for PCA vs 1·447 
for VAE; p=0·0001).
Outcome
The outcome for this analysis was all-cause mortality, 
which included additional deaths reported after the 
censor date for a number of included studies.4 Each 
trial performed independent adjudication of clinical 
outcomes. Assignment of outcomes in this study was 
based on an intention-to-treat approach according to the 
randomised group, regardless of treatment discon-
tinuation or cross over. There were no patients with 
missing vital status.
Clustering
The aim of the cluster analysis was to find similar 
subgroups within the cluster, yet dissimilar to other 
clusters (minimising intercluster similarity). Hierarchical 
clustering (iteratively merging samples to form groups) 
and k-means++ (iteratively assigning samples to cluster 
centres) were used as the underlying clustering tech-
niques. The number of clusters and the number of 
dimensions used were objectively established by iteratively 
repeating clustering and then selecting the model with 
the highest gap statistic value, followed by evaluation 
with three performance measures (figure 1; appendix 
pp 3–5, 14). The gap statistic measures the result of the 
clustering of the data versus a random model using 
the same number of clusters. The higher the gap value, the 
less likely the identified clusters were assigned at random. 
Radar plots were used to visually describe the generated 
clusters for key demographic characteristics. The plots 
were generated by scaling or normalising (or both) the 
median of that specific cluster to the median of the com-
plete cohort, or mean percentage for categorical variables.
Evaluation and validation protocol
Clustering was further evaluated for robustness and 
validation. The robustness of the approach was confirmed 
using repeated clustering (k=100) of random subsets 
of the data (bootstrapping), comparing the resulting 
clustering against random cluster assign ments.16 The 
Figure 1: Study flowchart
ECG=electrocardiogram. LVEF=left ventricular ejection fraction. RCTs=randomised controlled trials. *Age, gender, body-mass index (missing n=148), heart rate 
(missing n=5), systolic blood pressure (missing n=7), LVEF, previous myocardial infarction (missing n=43), New York Heart Association symptom class (missing n=83), 
creatinine (missing n=101), baseline drug therapy (angiotensin converting enzyme inhibitor or angiotensin receptor blocker, diuretics, anticoagulants [missing n=1] 
and digoxin), and other than sinus rhythm or atrial fibrillation or flutter on baseline ECG (n=506). 32 patients had more than one variable missing. †MDC, US-HF, ANZ, 
CIBIS-II, MERIT-HF, COPERNICUS, CAPRICORN, BEST, and SENIORS (appendix p 16).
18 637 individual patient data quality improved and
harmonised from 11 RCTs
Machine learning approach Objective metrics
15 659 individual patient data from nine double-blind
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of clustering) 
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dimensions and clusters)  









12 822 sinus rhythm on baseline ECG
(including 2028 deaths) 
2837 atrial fibrillation on baseline ECG
(including 578 deaths)
Optimal objective model:
nine dimensions and six clusters
Optimal objective model:
nine dimensions and five clusters
2978 individual patient data excluded
 334 LVEF at baseline ≥50%
 91 missed LVEF 
 112 missing ECG at baseline
 599 paced rhythm
 627 participants in CIBIS I
 358 participants in CHRISTMAS
 857 participants without complete
 baseline case data*
Articles
1430 www.thelancet.com   Vol 398   October 16, 2021
overlap of clusters was identified using the weighted 
Jaccard score, and the comparison to random assignment 
assessed using the Kolmogorov–Smirnov test. Validation 
of the overall approach was shown by repeatedly 
generating clusters, with each iteration leaving one trial 
out. Because each trial is unique, with its own selection 
criteria, this approach provided external validation of 
clustering results. The Adjusted Rand Index (ARI) was 
used to measure the agreement between the clustering 
approaches compared with a random model. Further 
details on the clustering and evaluation approaches used 
are presented in the appendix (pp 2–6).
Statistical analysis
A statistical analysis plan was generated and finalised in 
advance of data analysis. Summary results are presented 
as percentages, or median (IQR). Group comparisons 
were made using the Kruskal-Wallis non-parametric 
rank test. We calculated the odds ratios (ORs) and risk 
ratios for each cluster assignment by splitting each 
cluster into placebo and β blocker treatment and 
accounting for all sources of death. The number needed 
to treat (NNT) was calculated as the inverse of the 
absolute risk reduction (ARR) comparing β blockers 
with placebo. A two-tailed p value of 0·05 was considered 
statistically significant. Analyses were performed using 
the Python library statsmodel (version 0.12.1) on Python 
(version 3.7.2), and Stata (version 14.2).
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report.
Results
From the nine trials, 15 659 patients with HFrEF were 
included, with median age of 64 years (IQR 55–72); 
3708 (24%) of the patients were women. Median LVEF 
was 27% (IQR 21–33), with the majority of patients 
reporting severe or disabling symptoms (table 1). 
According to their baseline ECG, 12 822 patients were in 
sinus rhythm and 2837 patients were in atrial fibrillation 
(figure 1). Individuals with atrial fibrillation were older 
with lower rates of previous myocardial infarction, but 
similar heart rate, blood pressure, and LVEF compared 
with patients in sinus rhythm. Due to the randomisation 
in each trial, there were no differences in patient 
characteristics between β blockers or placebo for either 
sinus rhythm or atrial fibrillation (appendix p 8). The 
median follow-up period was 1·3 years (IQR 0·9–1·9).
Across the whole cohort of patients in sinus rhythm 
(n=12 822), β blockers significantly reduced all-cause 
mortality compared with placebo, with an adjusted OR 
of 0·74 (95% CI 0·67–0·81; p<0·001). Of the patients 
randomly assigned to β blockers, 907 (13·9%) of 
6546 died, compared with 1121 (17·9%) of 6276 allocated 
to placebo.
The optimal VAE clustering for the primary analysis 
model in sinus rhythm used nine dimensions and 
six clusters (SR1–SR6). The majority of clusters showed 
a consistent benefit from β blockers on mortality across 
the risk of death, ranging from OR of 0·54 to 0·74 
(table 2; figure 2). This included the two largest clus-
ters, cluster SR5 encompassing younger patients with 
predominantly non-ischaemic cause (NNT 22·9), and 
SR6 including patients with the lowest LVEF and 
highest annualised death rate of 19·6% (NNT 17·4). 
The OR was stable in the smallest clusters—eg, SR1 at 
the lower end of mortality risk (annualised 3·9%), 
although the small sample size precluded statistical 
significance. Despite a large sample size (n=2537) and 
mid-range mortality risk (annualised 8·8%), cluster 
SR4 demonstrated no significant efficacy (OR 0·86, 
95% CI 0·67–1·10; p=0·22), with cluster interrogation 
suggesting older patients with less severe symptoms 
and lower heart rate than average (appendix p 9). We 
evaluated the distribution of individual patient data and 
found a broad representation of trials across each 
cluster. Additional models were consistent regardless 
of the number of clusters (appendix p 15).
Robustness of clustering in sinus rhythm was 
confirmed, with good repeatability of the clustering 
approach using bootstrap methods (mean Jaccard 
score 0·575 [SD 0·103], compared with 0·121 [SD 0·005] 
with random assignment; p<0·0001). The validity pro-
tocol demonstrated consis tency of cluster membership 
prediction in the leave-one-study-out approach (average 
ARI of 0·493 [SD 0·092]; appendix p 10) and for 
the predicted cluster membership in the left-out trials 
(average ARI 0·569 [SD 0·052]), which were significantly 







Age, years 64 (55–72) 64 (54–71) 69 (60–74)
Sex
Women 3708 (23·7%) 3185 (24·8%) 523 (18·4%)
Men 11 951 (76·3%) 9637 (75·2%) 2314 (81·6%)
Body-mass index, kg/m² 26·6 (24·0–29·8) 26·6 (24·0–29·7) 26·9 (24·3–30·1)
Heart rate, beats per min 80 (72–88) 80 (72–88) 81 (72–92)
Systolic blood pressure, mm Hg 124 (110–140) 123 (110–139) 126 (113–140)
LVEF 27% (21–33) 27% (21–33) 27% (21–33)
Previous myocardial infarction 8538 (54·5%) 7411 (57·8%) 1127 (39·7%)
NYHA class III or IV 8802 (63·7%) 7048 (61·9%) 1754 (72·6%)
Creatinine, μmol/L 105 (88–124) 104 (88–124) 108 (90–131)
ACEi or ARB 14 877 (95·0%) 12 188 (95·1%) 2689 (94·8%)
Any diuretic therapy 13 563 (86·6%) 10 914 (85·1%) 2649 (93·4%)
Anticoagulation therapy 5033 (32·1%) 3379 (26·4%) 1654 (58·3%)
Digoxin 9299 (59·4%) 6919 (54·0%) 2380 (83·9%)
Data are median (IQR) or n (%). Breakdown according to randomised treatment allocation (β blockers vs placebo) is 
provided in the appendix (p 8). ACEi=angiotensin converting enzyme inhibitor. ARB=angiotensin receptor blocker. 
LVEF=left ventricular ejection fraction. NYHA=New York Heart Association.
Table 1: Baseline characteristics
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Across the whole cohort of patients in atrial fibrillation 
(n=2837), β blockers did not significantly reduce all-
cause mortality compared with placebo, with an adjusted 
OR of 0·92 (95% CI 0·77–1·10; p=0·37). In participants 
randomly assigned to β blockers, 278 (19·7%) of 
1412 died, compared with 300 (21·1%) of 1425 allocated 
to placebo.
The optimal VAE clustering in atrial fibrillation 
used nine dimensions and five clusters (AF1–AF5). 
Consistent with the overall efficacy results, clusters AF1, 
AF3, and AF5 demonstrated no significant reduction in 
mortality with β blockers (table 2; figure 3). A lack of 
efficacy was also noted in cluster AF4, comprised of 
patients with low LVEF and markedly elevated mortality 
risk (annualised 28·4%). Compared with placebo, there 
was a statistically significant reduction in mortality with 
β blockers in cluster AF2, with an adjusted OR of 0·57 
(95% CI 0·35–0·93; p=0·023) and NNT of 17·4. This 
cluster (n=659) was comprised of younger patients with 
lower rates of previous myocardial infarction, but 
Annualised 
mortality
Placebo β blockers Odds ratio (95% CI) Risk ratio (95% CI) p value Number needed 
to treat (95% CI)
SR
SR all 15·8% 1121/6276 (17·9%) 907/6546 (13·9%) 0·74 (0·67–0·81) 0·86 (0·81–0·90) <0·0001 25 (18–39)
SR1 3·9% 14/222 (6·3%) 8/211 (3·8%) 0·59 (0·24–1·43) 0·74 (0·41–1·29) 0·23 NA
SR2 5·7% 40/487 (8·2%) 34/514 (6·6%) 0·79 (0·49–1·27) 0·89 (0·69–1·14) 0·33 NA
SR3 9·1% 108/731 (14·8%) 59/683 (8·6%) 0·54 (0·39–0·76) 0·71 (0·57–0·87) 0·0004 16 (11–36)
SR4 8·8% 151/1231 (12·3%) 140/1306 (10·7%) 0·86 (0·67–1·10) 0·93 (0·82–1·05) 0·22 NA
SR5 10·3% 267/1706 (15·7%) 202/1791 (11·3%) 0·69 (0·56–0·83) 0·82 (0·74–0·92) 0·0001 23 (15–47)
SR6 19·6% 541/1899 (28·5%) 464/2041 (22·7%) 0·74 (0·64–0·85) 0·86 (0·80–0·93) <0·0001 17 (12–33)
AF
AF all 20·4% 300/1425 (21·1%) 278/1412 (19·7%) 0·92 (0·77–1·10) 0·96 (0·87–1·05) 0·37 NA
AF1 13·8% 50/307 (16·3%) 59/301 (19·6%) 1·25 (0·83–1·90) 1·12 (0·92–1·36) 0·29 NA
AF2 9·2% 50/338 (14·8%) 29/321 (9·0%) 0·57 (0·35–0·93) 0·73 (0·54–0·98) 0·023 17 (9–119)
AF3 15·1% 68/348 (19.5%) 69/348 (19·8%) 1·02 (0·70–1·48) 1·00 (0·84–1·22) 0·92 NA
AF4 28·4% 81/201 (40·3%) 68/202 (33·7%) 0·75 (0·50–1·13) 0·87 (0·70–1·07) 0·17 NA
AF5 17·0% 51/231 (22·1%) 53/240 (22·1%) 1·00 (0·65–1·55) 1·00 (0·81–1·24) 1·0 NA
Data are % or n/N (%), unless stated otherwise. Results are based on objective assessment for the number of dimensions and clusters for sinus and atrial fibrillation, as defined 
by the gap statistic. NA=not applicable as the absolute risk reduction with β blockers is not significant. SR=sinus rhythm. AF=atrial fibrillation.
Table 2: Cluster-specific results for all-cause mortality
Figure 2: Clustering for all-cause mortality and β-blocker efficacy in SR
Green circles represent the average mortality risk, with size relative to the number of patients in that cluster. ORs (95% CI) are for the efficacy of β blockers versus placebo for all-cause mortality; 
odds below the dotted line indicate a benefit from β blockers. Radar plots summarise scaled variables for each cluster, with the average for the whole cohort of sinus rhythm patients noted in orange. 
Values closer to the outer ring are higher than the cohort average for each of the key variables. Other variables not displayed in the radar plots include: systolic blood pressure, New York Heart 
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similar LVEF to the average atrial fibrillation patient 
(appendix p 11). Although still elevated compared with 
most sinus rhythm patients, annualised mortality was 
the lowest of any atrial fibrillation cluster (9·2%).
Robustness of cluster membership in atrial fibrillation 
was confirmed, with a mean Jaccard score of 0·571 
(SD 0·073; p<0·0001 vs random). The leave-one-study-
out protocol confirmed validity (appendix p 12), with 
consistent ARI values for the iteration set (average 0·551 
[SD 0·156]) and for the left-out study prediction 
(average 0·532 [SD 0·276]), which were significantly 
different to random (p=0·0264).
Discussion
Application of a novel machine learning approach 
within RCTs was able to define clusters of treatment 
response for β blockers in patients with HFrEF. In 
sinus rhythm, specific clusters were identified where 
β blockers had suboptimal impact on mortality. 
Conversely, despite an overall lack of efficacy from 
β blockers in individuals with atrial fibrillation, this 
approach was able to identify a subgroup of atrial 
fibrillation patients where β blockers did reduce death. 
Clustering was based on objective assessment, and the 
robustness and validation protocols provide reassurance 
of the consistency and repeatability of findings. 
Development and application of these processes could 
facilitate an individualised approach to treatment 
selection that accounts for comorbidities, thereby 
contributing to improvements in patient wellbeing.
Heart failure continues to present an enormous and 
costly challenge for health-care services. Patients with 
heart failure are increasingly multimorbid, with the 
majority now with three or more comorbidities.17 
Non-cardiac comorbidities can have a different clinical 
impact on heart failure, both for adverse events18 and 
patient-related health outcomes.19 Multimorbidity also 
complicates the management of patients with heart 
failure and adds to the challenge of identifying who, in 
routine practice, will benefit from recommended 
medication, or should be considered or referred for 
alternative therapy. Although the prevalence of comor-
bidities in HFrEF trials has increased over time, so have 
exclusion criteria for chronic kidney disease, anaemia, 
atrial fibrillation, and chronic lung and liver disease,20 
making it more difficult to apply evidence to individual 
patients. Tools that can aid clinicians to stratify potential 
treatment responses are urgently needed to curtail the 
burden of heart failure on health and social care.21 There 
is also an opportunity to facilitate new clinical research 
and identify new drug targets. Atrial fibrillation is a 
prime example due to the excess morbidity and 
mortality when associated with HFrEF, and the lack of 
supporting evidence for many of the therapies currently 
recommended in clinical guidelines.22,23
In this study, we developed and used a novel com-
bination of machine learning methods to demonstrate the 
value of assessing the interaction of factors related 
to β-blocker efficacy in higher dimensions, which is 
not possible with conventional statistical analysis. Our 
Figure 3: Clustering for all-cause mortality and β-blocker efficacy in AF
Blue circles represent the average mortality risk, with size relative to the number of patients in that cluster. ORs (95% CI) are for the efficacy of β blockers versus 
placebo for all-cause mortality; odds below the dotted line indicate a benefit from β blockers. Radar plots summarise scaled variables for each cluster, with the 
average for the whole cohort of atrial fibrillation noted in orange. Values closer to the outer ring are higher than the cohort average for each of the key variables. 
Other variables not displayed in the radar plots include: systolic blood pressure, New York Heart Association symptom class, creatinine, and baseline drug therapy 
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approach started with the use of neural network-based 
autoencoders to isolate key features in the data, while 
capturing the latent and underlying structure of complex 
data interactions without reliance on preconceived 
hypotheses. Objective selection of the number of 
dimensions and clusters was done, which in previous 
studies is often at the discretion of researchers and 
hence subject to considerable (and unquantifiable) bias. 
Iterative hierarchical clustering was then tested by a 
thorough evaluation of robustness and consistency, in 
addition to repeated external validation using a leave-one-
trial-out approach. Our rationale was to ensure confidence 
in the results of clustering for β-blocker efficacy, addressing 
often stated limitations in the value of clustering methods. 
Unlike previous studies that have clustered data from 
observational cohorts,24 we used the highest quality data 
obtained and harmonised from landmark, placebo-
controlled RCTs with adjudicated endpoints.
Although tested in trials of β blockers, these approaches 
based on simple parameters have clear potential across 
the spectrum of therapies in heart failure, and across 
other cardiovascular and non-cardiovascular conditions. 
In sinus rhythm, we identified clusters of patients with 
reduced mortality benefit from β-blocker therapy, a 
clinically important finding that could allow targeting of 
alternative therapies to address the high residual rate of 
adverse outcomes in patients with HFrEF (despite 
optimal medical treatment). Notably for the lack of 
efficacy in the cluster with less severe symptoms, higher 
age, and lower heart rate; the combination of which 
would be consistent with the presumed mode of action of 
β blockers. The efficacies of different β blockers are 
known to depend on the disease substrate within each 
patient,25 in addition to genetic factors such as 
polymorphisms of the β1-adrenergic receptor.26 In atrial 
fibrillation, a cluster of patients was identified with a 
therapeutic response to β blockers—a significant 
reduction in mortality that was distinct from other 
clusters and the group as a whole. The potential gain 
from using these artificial intelligence approaches in 
clinical practice would be to isolate these patients and 
personalise their management, improving prognosis for 
this group, as well as avoiding adverse events from 
β blockers in those unlikely to receive prognostic benefit.
Approaches based on artificial intelligence are often 
criticised for their lack of transparency (black-box effect), 
although the point of these methods is often to go beyond 
conventional preconceptions of how data points are 
correlated. This does mean that translation to linear 
factor combinations is not possible. However, we have 
attempted to provide some underlying interrogation of 
the clustering approach by demonstrating how patients 
within each cluster differ from each other across some 
key variables. The radar plots confirm our hypothesis 
about the value of higher-level interactions of clinical 
factors—eg, when comparing the sinus rhythm cluster 
SR3 with SR4 (different β-blocker effectiveness) and SR6 
(markedly different mortality rate). In atrial fibrillation, 
the cluster demonstrating benefit from β blockers 
primarily consisted of younger patients at lower overall 
mortality risk. This result could be consistent with 
patients with a less severe atrial fibrillation phenotype,27 
and before the onset of multimorbidity that is critical 
to adverse outcomes in atrial fibrillation.28 Other 
advanced bioinformatic techniques in heart failure have 
used latent class analysis to define distinct comorbidity 
clusters with respect to heart failure rehospitalisation 
and mortality,29 and neural networks to predict incident 
heart failure in electronic health records.30 We are not 
aware of any previous approaches that have used such 
extensive validation of the assignment to clusters, 
reassignment to clusters, and also the predicted effects 
across different datasets.
As with any machine learning clustering approach, 
some degree of randomness is inevitably introduced 
during the embedding and dimensionality reduction 
steps. This is a desired approach to avoid suboptimal 
embeddings, and repeatability of findings was shown in 
the leave-one-trial-out validation protocol. Although the 
trial data cover a period before the routine use of cardiac 
resynchronisation therapy, neprilysin inhibition, and 
more recently gliflozins, the evidence base for all of 
these heart failure therapies is based on pre-existing 
renin-angiotensin and β1 adrenoreceptor blockade. Our 
study is limited to the outcome of mortality to avoid 
confounding by indication with hospitalisation and 
competing risk; further work is in progress to develop 
novel machine learning methodology. A particular 
strength of our data is the use of individual patient-level 
data from landmark RCTs that were carefully harmonised 
and quality controlled before analysis. The heart rhythm 
for each patient was established using their baseline 
ECG; while this is a more robust way to ascertain atrial 
fibrillation than clinical history, we might have missed 
patients with paroxysmal atrial fibrillation and had 
no information on the duration or burden of atrial 
fibrillation. Finally, this cohort consists of patients with 
HFrEF (primarily at the more severe end) and so the 
results might not apply to atrial fibrillation patients 
without a clinical diagnosis of heart failure.
This study has demonstrated the potential clinical value 
of combining a series of robust artificial intelligence-
based approaches to better identify clusters of treatment 
response for a fundamental therapy used in patients with 
heart failure. The unsupervised and validated approach 
was able to consistently identify patient subgroups in 
sinus rhythm with suboptimal efficacy from β blockers, 
and importantly a subgroup of patients with atrial 
fibrillation in whom β blockers significantly reduced the 
risk of death despite an overall neutral response. The 
results warrant further validation across other treatments 
and conditions, followed by prospective evaluation to 
confirm if using such methods to direct the choice of 
therapy can improve patient outcomes.
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